TaiMed Biologics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

TaiMed Biologics şirketinin toplam hissedar öz sermayesi NT$4.1B ve toplam borcu NT$502.0M olup, bu da borç-öz sermaye oranını 12.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$5.7B ve NT$1.6B dir.

Anahtar bilgiler

12.1%

Borç/özkaynak oranı

NT$501.99m

Borç

Faiz karşılama oranı	n/a
Nakit	NT$2.18b
Eşitlik	NT$4.15b
Toplam yükümlülükler	NT$1.59b
Toplam varlıklar	NT$5.73b

Son finansal sağlık güncellemeleri

TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

Dec 01

Recent updates

TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

Apr 20

TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

Mar 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4147 'nin kısa vadeli varlıkları ( NT$4.1B ) kısa vadeli yükümlülüklerini ( NT$722.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4147 şirketinin kısa vadeli varlıkları ( NT$4.1B ) uzun vadeli yükümlülüklerini ( NT$864.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4147 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4147 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 12.1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan 4147 mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: 4147 kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 41.8 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

TaiMed Biologics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Taimed Biologics Inc. Receives Patent Approval from China for Improving the Pharmacokinetic Performance of Tmb-365 Using Histidine Modification Technology

No longer forecast to breakeven

Price target increased by 17% to NT$152

Second quarter 2024 earnings: Revenues exceed analyst expectations

TaiMed Biologics Inc. to Report Q2, 2024 Results on Aug 08, 2024

TaiMed Biologics Inc. Receives Patent Approval from the US PTO for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy

TaiMed Biologics Inc. to Report Q1, 2024 Results on May 13, 2024

New minor risk - Shareholder dilution

Forecast breakeven date moved forward to 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

TaiMed Biologics Inc., Annual General Meeting, May 28, 2024

Forecast breakeven date moved forward to 2024

Consensus revenue estimates decrease by 25%

No longer forecast to breakeven

TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology

TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection

Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo

TaiMed Biologics Inc. has filed a Follow-on Equity Offering.

TaiMed Biologics Inc. has filed a Follow-on Equity Offering.

TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Profitability

TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution

Forecast to breakeven in 2024

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy

Consensus revenue estimates decrease by 56%, EPS upgraded

Consensus revenue estimates decrease by 29%, EPS upgraded

Price target increased by 31% to NT$133

Forecast to breakeven in 2024

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

TaiMed Biologics Inc. Announces First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy

TaiMed Biologics Inc. Approves Board Appointments

TaiMed Biologics Inc. Receives Official Approval Letter from US FDA

First quarter 2022 earnings: EPS exceeds analyst expectations

Consensus revenue estimates fall by 48%

Forecast breakeven date pushed back to 2023

TaiMed Biologics Inc. Announces Enrollment of Phase III Clinical Study is Complete for Trogarzo Intramuscular Injection (IM)

Price target increased to NT$109

Less than half of directors are independent

Forecast breakeven date pushed back to 2023

TaiMed Biologics Inc. Announces Change of CEO

Taimed Biologics Inc. Announces FDA Approves 1b/2a Clinical Studying Two Monoclonal Antibody

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to NT$109

TaiMed Biologics Inc. Submits Initial Safety and Efficacy Results of the Phase I Clinical Trial of Tmb-365 to the US Food and Drug Administration

TaiMed Biologics Inc. Announces US FDA Approves Supplemental BLA Filing for the Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo

Taimed Biologics Inc. Announces the Presentation of Positive Results from Trogarzo IV Push Administration Study

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings released: NT$0.31 loss per share (vs NT$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.12 profit in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.02 (vs NT$0.30 loss in 1Q 2020)

TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook

Full year 2020 earnings released: NT$0.73 loss per share (vs NT$2.30 loss in FY 2019)

TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%

TaiMed Biologics Inc., Annual General Meeting, May 31, 2021

TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.

New 90-day low: NT$78.60

Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven

New 90-day low: NT$85.90

TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?

Revenue and earnings miss expectations

Third quarter 2020 earnings released: NT$0.18 loss per share

New 90-day low: NT$86.20

Price target raised to NT$143

New 90-day high - NT$112

Price target raised to NT$125

First half earnings released